Goldenrod Therapeutics Announces Abstract Accepted for Presentation at The International Society of Addiction Medicine’s (ISAM) 2022 World Congress Meeting
Meeting Presentation Will Feature Data Demonstrating Promise of Goldenrod Novel Drug in the Treatment of Substance Use Disorders
Houston, TX (July 21, 2022) - Goldenrod Therapeutics, a bio-pharmaceutical company under the Fannin (www.fannininnovation.com) portfolio, today announced that outcomes of its pivotal pre-clinical study on the efficacy of the small molecule drug 11h in substance use disorders were selected for a presentation at Society of Addiction Medicine’s (ISAM) 2022 World Congress Meeting. ISAM’s Congress Meeting, this year will be held in-person in Valletta, Malta, as well as virtually. As in past years, the World Congress will emphasize ISAM’s mission of increasing knowledge about addiction as a treatable disease.
The presentation will cover novel findings on Goldenrod’s novel therapeutic 11h, a specific phosphodiesterase 4B inhibitor to reduce inflammation and normalize neurotransmitter release. In new studies done in a mouse model of substance use disorder, 11h inhibited the animals’ opioid as well as cocaine self-administration. The presentation at the World Congress Meeting will be given by Dr. Elise Waldron-Young, Pharm.D., Ph.D, Fellow at Fannin Innovation Studio, and a Principal Investigator in the Goldenrod study on 11h. “This presentation is an excellent opportunity to showcase promising new data on 11h, and its potential as a novel treatment of opioid as well as other substance use disorders,” said Dr. Waldron-Young.
Goldenrod’s efforts in developing the compound come at a time when innovative treatments for opioid use disorder are direly needed as deaths due to opioid use and overdose continue to rise. Drugs like 11h have been in development for the past several years; however, they differ from 11h in one critical aspect – they are typically associated with severe gastrointestinal side effects, while Goldenrod’s new drug is not. “11h’s tolerability in addition to its wide potential applications will certainly make for good discussion with our international colleagues at the World Congress Meeting, and we truly value the opportunity to raise excitement about our and our collaborators’ work with the international medical community,” said Dr. Waldron-Young.
Goldenrod’s work on 11h is funded by the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) through a grant that supports continuing pre-clinical and toxicology studies on the small molecule. Goldenrod Therapeutics is a virtual company within the portfolio of Fannin, an early-stage life science management and investment company based in Houston, TX. “We are tremendously excited to share updates on and novel prospects of our innovative technology, the development of which is made possible thanks to esteemed support from the NIH,” said Dr. Atul Varadhachary, M.D., Ph.D., Managing Partner at Fannin Innovation Studio.
About Fannin
Houston-based Fannin is an early-stage life sciences development group focused exclusively on commercializing medical technologies. Fannin partners with life science innovators to co-found startup companies by providing a pooled experienced management team, central office space and seed funding. To further bridge the commercialization gap, Fannin’s apprenticeship program provides aspiring entrepreneurs with hands-on development experience with its portfolio companies. For more information, visit www.FanninInnovation.com or email innovate@fannininnovation.com.